Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Lillian L. Siu, Neeltje Steeghs, Tarek Meniawy, Markus Joerger, Jennifer L. Spratlin, Sylvie Rottey | ||||||||||||
Title | Preliminary results of a phase I/IIa study of BMS-986156 (glucocorticoid-induced tumor necrosis factor receptor–related gene [GITR] agonist), alone and in combination with nivolumab in pts with advanced solid tumors. | ||||||||||||
|
|||||||||||||
URL | http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.104#affiliationsContainer | ||||||||||||
Abstract Text | Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 104-104 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
BMS-986156 | BMS-986156 | 0 | 1 |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BMS-986156 | BMS986156|BMS 986156 | GITR Antibody 6 | BMS-986156 is an activating monoclonal antibody that binds to TNFRSF18 (GITR, CD357), which leads to the activation of effector T cells and a decrease in T-regulatory cells, subsequently resulting in antitumor activity (Journal of Clinical Oncology 35, no. 15_suppl (May 2017) 104-104, PMID: 31697308). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|